Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cybin (CYBN)
NYSE MKT:CYBN
Holding CYBN?
Track your performance easily
CYBN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.17 - $13.88
Previous Close$10.16
Volume523.19K
Average Volume (3M)2.01M
Market Cap
$1.31M
Enterprise Value-$129.72M
Total Cash (Recent Filing)C$183.28M
Total Debt (Recent Filing)C$212.00K
Price to Earnings (P/E)―
Beta0.11
Next Earnings
Feb 18, 2025EPS Estimate
-$0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.98
Shares Outstanding19,991,908
10 Day Avg. Volume940,984
30 Day Avg. Volume2,011,924
Standard Deviation1.14
R-Squared0.09
Alpha0.08
Financial Highlights & Ratios
Price to Book (P/B)0.80
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$103.75Price Target Upside997.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Cybin News
PremiumCompany Announcements
Cybin’s CYB003 Shows Promising Results for DepressionBulls Say, Bears Say
Bulls Say
Clinical Trial ResultsThe 12-month efficacy data for CYB003 in major depressive disorder is described as stellar, with significant improvements observed in patients.
Market PotentialIf later-stage trial results are similar to current findings, CYB003 could become a game-changing adjunct treatment for major depressive disorder.
Safety ProfileCYB003 has demonstrated a consistently favorable safety profile, with no new adverse events reported.
Bears Say
Clinical Development And Regulatory RisksRisks include clinical development risk tied to CYB003, CYB004, and CYB005, along with competitor and regulatory risks.
Financial PerformanceCYBN's operating expenses exceeded expectations due to significant share-based compensation related to recent senior hires and milestones achieved.
Regulatory DelaysCompass Pathways provided a business update, disclosing delays to the top-line results release for their COMP360 phase 3 trials.
---
Ownership Overview
Currently, No data available
---
CYBN FAQ
What was Cybin’s price range in the past 12 months?
Cybin lowest stock price was $0.17 and its highest was $13.88 in the past 12 months.
What is Cybin’s market cap?
Currently, no data Available
When is Cybin’s upcoming earnings report date?
Cybin’s upcoming earnings report date is Feb 18, 2025 which is in 87 days.
How were Cybin’s earnings last quarter?
Cybin released its earnings results on Nov 11, 2024. The company reported -$2.047 earnings per share for the quarter, missing the consensus estimate of -$0.025 by -$2.022.
Is Cybin overvalued?
According to Wall Street analysts Cybin’s price is currently Undervalued.
Does Cybin pay dividends?
Cybin does not currently pay dividends.
What is Cybin’s EPS estimate?
Cybin’s EPS estimate is -$0.75.
How many shares outstanding does Cybin have?
Cybin has 19,991,910 shares outstanding.
What happened to Cybin’s price movement after its last earnings report?
Cybin reported an EPS of -$2.047 in its last earnings report, missing expectations of -$0.025. Following the earnings report the stock price went up 11.317%.
Which hedge fund is a major shareholder of Cybin?
Currently, no hedge funds are holding shares in CYBN
---
Cybin Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$103.75 (997.88% Upside)
$103.75 (997.88% Upside)
Blogger Sentiment
Bullish
CYBN Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.4%
Last 30 Days ▲ 25.0%
Last 30 Days ▲ 25.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
2075.58%
12-Months-Change
Fundamentals
Return on Equity
-80.93%
Trailing 12-Months
Asset Growth
355.68%
Trailing 12-Months
Company Description
Cybin
Using cutting-edge drug discovery platforms and drug delivery systems, Cybin develops psychedelic therapies to address the mental health crisis.
---
CYBN Stock 12 Month Forecast
Average Price Target
$103.75
▲(997.88% Upside)
Technical Analysis
Best Analysts Covering CYBN
1 Year
1 Year Success Rate
12/22 ratings generated profit
1 Year Average Return
+310.82%
reiterated a buy rating 4 days ago
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +310.82% per trade.
---